Trump vs. Big Pharma: Art of the Deal or Just Another Executive Order?

Listen on: Apple Podcasts:https://podcasts.apple.com/us/podcast/watchdog-on-wall-street-with-chris-markowski/id570687608 Spotify: https://open.spotify.com/show/2PtgPvJvqc2gkpGIkNMR5i Watch on: https://www.youtube.com/@WatchdogOnWallstreet/featured Chris breaks down Trump’s executive order aimed at lowering U.S. prescription drug prices—and why it likely won’t survive a legal challenge. He explains how Americans bear the brunt of global R&D costs due to foreign price controls and argues that real reform lies in negotiation, not government-mandated price fixing. Markowski draws from his experience in pharmaceutical investment banking to expose the high stakes of drug development and offers potential “Art of the Deal” tactics Trump could use—like restricting pharma ad spending—to push foreign governments to pay their fair share. He warns that true price controls would kill innovation and devastate the industry. www.watchdogonwallstreet.com